Vigil Neuroscience Inc

Vigil Neuroscience — Technical Presentation (November 2023)

56 slides from Vigil Neuroscience's technical presentation, Nov 16, 2023

  1. Slide 1: Interim Analyses of ILLUMINATE Natural History Study & IGNITE Phase 2 Trial

    Interim Analyses of ILLUMINATE Natural History Study & IGNITE Phase 2 Trial for Iluzanebart (VGL101) in ALSP November 16, 2023 Exhibit 99.2

  2. Slide 2: Today's Agenda

    Today’s Agenda 4:30 - 4:35 PM (5 min) Opening Remarks and Corporate Overview Ivana Magovčević-Liebisch, PhD, JD President & Chief Executive Officer, Vigil Neuroscience, Inc. 4:35 - 5:05 PM (30 min) Presentation of Iluzanebart (VGL101) Interim Data from Phase 2 IGNITE Study in ALSP & Ongoing ILLUMINA

  3. Slide 3: Reminders

    Reminders Webinar scheduled to end at 5:30pm ET Presentation is available in investors section under Events & Presentations at www.vigilneuro.com Moderated Q&A session following prepared remarks To submit a written question, fill out form on webcast home page Webcast replay available later today on

  4. Slide 4: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements,” which are made pursuant to the safe harbor provisions of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact may be d

  5. Slide 5: Corporate Overview

    Corporate Overview Ivana Magovčević-Liebisch, PhD, JD Chief Executive Officer Vigil Neuroscience, Inc. © Vigil Neuroscience, Inc. 2023. All rights reserved.

  6. Slide 6: Overall Summary

    Overall Summary ILLUMINATE NHS continues to provide important insights and a rich dataset on biomarkers and clinical measures of disease progression in ALSP Totality of data, including longitudinal progression observed on selected MRI measures and clinical endpoints, support engagement with regulato

  7. Slide 7: Vigil Neuroscience

    Vigil Neuroscience Vigil Neuroscience is a clinical-stage microglia-focused therapeutics company Founded ~3 years ago in July 2020 Our purpose: to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the brain’s sentinel immune cells Precision-based strategy for

  8. Slide 8: Featured Key Opinion Leader (KOL)

    Featured Key Opinion Leader (KOL) David S. Lynch, MD, PhD Consultant Neurologist, National Hospital for Neurology & Neurosurgery, Queen Square & UCL Institute of Neurology, London Clinical Lead, Adult Inherited White Matter Disorders Highly Specialist Service, NHS England © Vigil Neuroscience, Inc.

  9. Slide 9: ILLUMINATE Natural History Study Updated Interim Analysis

    ILLUMINATE Natural History Study Updated Interim Analysis

  10. Slide 10: ILLUMINATE Updated Interim Analysis: Executive Summary

    ILLUMINATE Updated Interim Analysis: Executive Summary sCSF1R and NfL levels are remarkably altered in ALSP, which are key biomarkers of disease pathology Totality of data, including longitudinal progression observed on selected MRI measures and clinical endpoints, support engagement with regulatory

  11. Slide 11: First ALSP Natural History Study: Design

    First ALSP Natural History Study: Design First ever multicenter†, natural history study of ALSP patients with confirmed CSF1R gene mutation Sample size: ~50 subjects (globally) Objectives: Characterize biomarkers & clinical measures of disease progression in ALSP Possibility for external comparator

  12. Slide 12: Key Eligibility Criteria

    Key Eligibility Criteria ≥18 years of age with evidence of CSF1R gene mutation Symptomatic (Definitive) ALSP Subjects who fulfill both of the following criteria: More than two findings of clinical signs or symptoms in any of the following categories: Cognitive impairment or psychiatric problem Pyram

  13. Slide 13: Natural History Study Baseline Demography

    Natural History Study Baseline Demography Prodromal Symptomatic (N=18) (N=14) Age at Screening (yrs.) number 18 14 Mean (SE) 45.7 (4.0) 44.1 (2.8) Median 40.5 44 Sex Female: number (%) 11 (61.1%) 8 (57.1%) Male: number (%) 7 (38.9%) 6 (42.9%) Race White: number (%) 17 (94.4%) 14 (100.0%) Black: numb

  14. Slide 14: ILLUMINATE: Updated Interim Analysis on Fluid Biomarkers

    ILLUMINATE: Updated Interim Analysis on Fluid Biomarkers

  15. Slide 15: Fluid Biomarker Baseline Levels Altered in ALSP

    Fluid Biomarker Baseline Levels Altered in ALSP Healthy: healthy volunteers from VGL101 Phase 1 trial; CSF1R: Colony Stimulating Factor 1 Receptor; CSF: cerebrospinal fluid; NfL: neurofilament light chain Baseline NfL Levels in CSF (Left) & Serum (Right) sCSF1R levels reduced in prodromal and sympto

  16. Slide 16: ILLUMINATE: Updated Interim Analysis on MRI

    ILLUMINATE: Updated Interim Analysis on MRI

  17. Slide 17: ILLUMINATE MRI Markers of Disease Progression: Ventricular Volume

    ILLUMINATE MRI Markers of Disease Progression: Ventricular Volume Baseline Change from Baseline at Month 6 Symptomatic participants demonstrated greater ventricular expansion at baseline and progression over 6 months relative to prodromal participants Disease Progression Plots are Mean ± SE N=14 © V

  18. Slide 18: ILLUMINATE MRI Markers of Disease Progression: Gray Matter Volume

    ILLUMINATE MRI Markers of Disease Progression: Gray Matter Volume Baseline Change from Baseline at Month 6 Symptomatic participants demonstrated greater gray matter atrophy at baseline and progression over 6 months relative to prodromal participants Disease Progression © Vigil Neuroscience, Inc. 202

  19. Slide 19: ILLUMINATE: Interim Analysis on Clinical Endpoints

    ILLUMINATE: Interim Analysis on Clinical Endpoints

  20. Slide 20: Clinical Endpoint: Montreal Cognitive Assessment (MoCA)

    ILLUMINATE Clinical Endpoint: Montreal Cognitive Assessment (MoCA) Symptomatic participants demonstrated greater impairment at baseline and progression at 12 months N=51 N=4 N=11 N=4 N=7 N=4 N=6 Baseline MoCA MoCA Change from Baseline at Month 12 Disease Progression © Vigil Neuroscience, Inc. 2023.

  21. Slide 21: Clinical Endpoint: Cortical Basal Ganglia Functional Scale (CBFS)

    ILLUMINATE Clinical Endpoint: Cortical Basal Ganglia Functional Scale (CBFS) Symptomatic participants demonstrated greater impairment at baseline and progression at 12 months Baseline CBFS CBFS Change from Baseline at Month 12 Disease Progression © Vigil Neuroscience, Inc. 2023. All rights reserved.

  22. Slide 22: IGNITE Phase 2 Proof-of-Concept Trial of Iluzanebart in ALSP: 1st Interim Analysis

    IGNITE Phase 2 Proof-of-Concept Trial of Iluzanebart (VGL101) in ALSP 1st Interim Analysis Iluzanebart (VGL101) is an investigational therapy and has not been reviewed or approved by any regulatory authority

  23. Slide 23: IGNITE 1st Interim Analysis: Executive Summary

    IGNITE Phase 2 Trial 1st Interim Analysis: Executive Summary Favorable safety and tolerability data Most patients did not report treatment-related adverse events (AEs) No treatment-related severe or serious AEs No discontinuations due to AEs Predictable PK and brain penetration profile consistent wi

  24. Slide 24: IGNITE Open-Label Proof-of-Concept Trial Design

    Iluzanebart (VGL101) ALSP Phase 2 Open-Label Proof-of-Concept Trial Design © Vigil Neuroscience, Inc. 2023. All rights reserved. VGL101 (12 months, IV administration of 20mg/kg) Screening Follow up Primary Analysis: 6 months (all subjects) 20 mg/kg + 40 mg/kg Final Analysis: 12 months (all subjects)

  25. Slide 25: IGNITE Patient Population

    Iluzanebart (VGL101) ALSP Phase 2 Patient Population Key Clinical Inclusion Criteria Key Clinical Exclusion Criteria Documentation of a CSF1R gene mutation Clinical symptoms consistent with ALSP MRI findings consistent with ALSP Mild and early-moderate stages defined by cognitive and ambulation stat

  26. Slide 26: Phase 2 Baseline Demographics

    Phase 2 Baseline Demographics Phase 2 Baseline (N=6) Age at Screening (yrs.) n 6 Mean (SE) 40.3 (3.3) Median 41 Sex Female: n (%) 2 (33.3%) Male: n (%) 4 (66.7%) Race White: n (%) 5 (83.3%) Black: n (%) 1 (16.7%) Ethnicity Hispanic or Latino: n (%) 0 Not Hispanic or Latino: n (%) 5 (83.3%) Not State

  27. Slide 27: IGNITE Biomarkers of Pharmacology, Disease Progression and Clinical Endpoints

    Target Engagement (6 months) Microglia State (6 months) Disease Pathophysiology (6 -9 months) Clinical Progression (12 months) Fluid: sTREM2 (CSF) Fluid: sCSF1R (CSF) Osteopontin (CSF) Fluid: NfL (serum & CSF) Imaging: MRI measures ventricle and gray matter volumes Cognition & function: MoCA CBFS CD

  28. Slide 28: IGNITE Interim Safety Data Summary

    IGNITE Interim Safety Data Summary Favorable safety & tolerability profile Summary of Safety Outcomes (N=6)a Patients with TEAEs Any AE, n (%) 4 (66.7) Treatment-related AEs, n (%) 2 (33.3) Mildc 2 (33.3) Moderatec 1 (16.7) Severe 0 Treatment-related AEs occurring in ≥2 participants, n (%) 0 SAEs, n

  29. Slide 29: Iluzanebart PK in IGNITE

    Iluzanebart (VGL101) PK in IGNITE: Predictable and Consistent with Phase 1 Simulated median (line) PK and 95 % prediction interval (shaded) based on HVs at 20 mg/kg monthly. Dots are mean (+/- SD) of observed PK in ALSP patients Brain penetration and achieving projected CSF therapeutic exposures: ~0

  30. Slide 30: NfL Levels in CSF and Serum were Highly Correlated

    NfL levels in CSF and Serum were Highly Correlated © Vigil Neuroscience, Inc. 2023. All rights reserved. IGNITE Phase 2 Baseline

  31. Slide 31: Fluid Biomarker Data: Patient A

    Fluid Biomarker Data: Patient A CSF Biomarker Treatment effect Hypothesized* Observed** sTREM2 -26% sCSF1R +34% Osteopontin +32% Serum NfL at Phase 2 baseline: 80 pg/mL Serum NfL change in Natural History is estimated using patient’s own subject-level regression of ILLUMINATE and IGNITE baseline dat

  32. Slide 32: MRI Biomarker Data: Patient A

    MRI Biomarker Data: Patient A Gray Matter Volume Natural History IGNITE Ph2 Natural History IGNITE Ph2 + 10.0 mL - 3.8 mL Demonstrated directionally supportive changes in both MRI measures Ventricular Volume MRI change in Natural History estimated using patient own’s subject-level regression of ILLU

  33. Slide 33: Fluid Biomarker Data: Patient B

    Fluid Biomarker Data: Patient B CSF Biomarker Treatment effect Hypothesized* Observed** sTREM2 +60% sCSF1R +32% Osteopontin +7% Serum NfL at Phase 2 baseline: 159 pg/mL Serum NfL change in Natural History is estimated using patient’s own subject-level regression of ILLUMINATE and IGNITE baseline dat

  34. Slide 34: MRI Biomarker Data: Patient B

    MRI Biomarker Data: Patient B Natural History IGNITE Ph2 Natural History IGNITE Ph2 +50.4 mL Demonstrated directionally supportive changes in both MRI measures Gray Matter Volume Ventricular Volume -2.3 ml © Vigil Neuroscience, Inc. 2023. All rights reserved. MRI change in Natural History estimated

  35. Slide 35: Fluid Biomarker Data: Patient C

    Fluid Biomarker Data: Patient C CSF Biomarker Treatment effect Hypothesized* Observed** sTREM2 -5% sCSF1R -5% Osteopontin +20% Serum NfL at Phase 2 baseline: 42 pg/mL Serum NfL change in Natural History is estimated using patient’s own subject-level regression of ILLUMINATE and IGNITE baseline data

  36. Slide 36: MRI Biomarker Data: Patient C

    MRI Biomarker Data: Patient C Natural History IGNITE Ph2 Natural History IGNITE Ph2 - 54.1 mL + 1.6 mL Gray Matter Volume Ventricular Volume Did not demonstrate supportive changes in MRI measures © Vigil Neuroscience, Inc. 2023. All rights reserved. MRI change in Natural History estimated using pati

  37. Slide 37: Fluid Biomarker Data: Patient D

    IGNITE Ph2 Fluid Biomarker Data: Patient D CSF Biomarker Treatment effect Hypothesized* Observed** sTREM2 -20% sCSF1R +16% Osteopontin +18% Serum NfL at Phase 2 baseline: 10 pg/mL Serum NfL change in Natural History is estimated using patient’s own subject-level regression of ILLUMINATE and IGNITE b

  38. Slide 38: MRI Biomarker Data: Patient D

    IGNITE Ph2 MRI Biomarker Data: Patient D Natural History IGNITE Ph2 Natural History -6.8 mL - 0.2 mL Demonstrated directionally supportive change in ventricular volume Gray Matter Volume Ventricular Volume © Vigil Neuroscience, Inc. 2023. All rights reserved. MRI change in Natural History estimated

  39. Slide 39: Fluid Biomarker Data: Patient E

    Fluid Biomarker Data: Patient E CSF Biomarker Treatment effect Hypothesized* Observed** sTREM2 -26% sCSF1R +0% Osteopontin +9% Serum NfL at Phase 2 baseline: 12 pg/mL Serum NfL change in Natural History is estimated using patient’s own subject-level regression of ILLUMINATE and IGNITE baseline data

  40. Slide 40: MRI Biomarker Data: Patient E

    MRI Biomarker Data: Patient E Phase 2 Natural History Phase 2 -1.4 mL -1.2 mL Demonstrated directionally supportive change in ventricular volume Gray Matter Volume Ventricular Volume © Vigil Neuroscience, Inc. 2023. All rights reserved. Natural History MRI change in Natural History estimated using p

  41. Slide 41: Fluid Biomarker Data: Patient F

    Fluid Biomarker Data: Patient F CSF Biomarker Treatment effect Hypothesized* Observed** sTREM2 +14% sCSF1R +24% Osteopontin +118% Serum NfL at Phase 2 baseline: 54 pg/mL Serum NfL change in Natural History is estimated using patient’s own subject-level regression of ILLUMINATE and IGNITE baseline da

  42. Slide 42: MRI Biomarker Data: Patient F

    MRI Biomarker Data: Patient F Natural History IGNITE Ph2 IGNITE Ph2 +77.9 mL Demonstrated directionally supportive changes in both MRI measures Gray Matter Volume Ventricular Volume - 0.2 mL © Vigil Neuroscience, Inc. 2023. All rights reserved. Natural History MRI change in Natural History estimated

  43. Slide 43: MRI Changes on Gray Matter and Ventricular Volumes

    MRI Changes on Gray Matter and Ventricular Volumes Directional change indicating reduced progression rate in ventricular expansion and gray matter atrophy in certain patients post-iluzanebart (VGL101) treatment vs. pre-treatment Region Rate of Progression Ventricles 5 out of 6 patients had direction

  44. Slide 44: Changes in Biomarker Levels in CSF and Serum

    Changes in Biomarker Levels in CSF and Serum Encouraging directional changes in CSF and serum levels of biomarkers in certain patients post-iluzanebart (VGL101) treatment vs. pre-treatment Region Response on Fluid Biomarkers sCSF1R 4 out of 6 patients showed an increase over baseline (range: 16 – 34

  45. Slide 45: Overall Summary

    Overall Summary ILLUMINATE NHS continues to provide important insights and a rich dataset on biomarkers and clinical measures of disease progression in ALSP Totality of data, including longitudinal progression observed on selected MRI measures and clinical endpoints, support engagement with regulato

  46. Slide 46: ALSP Background & Perspectives on ILLUMINATE & IGNITE Interim Data

    ALSP Background & Perspectives on ILLUMINATE & IGNITE Interim Data David S. Lynch, MD, PhD Consultant Neurologist National Hospital for Neurology & Neurosurgery, Queen Square & UCL Institute of Neurology, London Clinical Lead Adult Inherited White Matter Disorders Highly Specialist Service, NHS Engl

  47. Slide 47: Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

    Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Rare autosomal dominant neurodegenerative disorder caused by mutation in the CSF1R gene1-7 Primarily causing degeneration of brain white matter Now recognized as ALSP ICD-10-CM Code G93.44 Estimated to affect 10%-25% of

  48. Slide 48: ALSP Symptoms

    ALSP Symptoms1,2 1. Sundal C, et al. CSF1R-Related Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia. In: Adam MP MG, et al, ed. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2023. 2. Konno T, et al. Eur J Neurol. 2017;24(1):37-45. Personality c

  49. Slide 49: Relentlessly Progressive ALSP

    Relentlessly Progressive ALSP Progression 75% survival for approximately 3 years, 50% for 5 years, 25% for 10 years and < 5% for 30 years Papapetropoulos et al. American Academy of Neurology Conference 2022 Kaplan-Meier estimates of survival probability (%) and number of patients at risk of death fo

  50. Slide 50: ALSP Pathophysiology – Genetically Caused

    ALSP Pathophysiology – Genetically Caused1 Loss of function mutations in the CSF1R gene leading to Microglia loss and dysfunction Structural and pathophysiological abnormalities of axons Demyelination of white matter Axonal spheroids2 Pigmented glia2 ALSP Gray Matter (IBA-1 Staining for Microglia)3

  51. Slide 51: Demonstration of ALSP Progression on MRI

    Demonstration of ALSP Progression on MRI Baseline 6 Month Scan 9 Month Scan F MRI scans of a symptomatic participant in Vigil’s ALSP natural history study, ILLUMINATE www.clinicaltrials.gov identifier: NCT05020743

  52. Slide 52: Significantly Elevated Serum NfL Levels in Symptomatic ALSP vs Other Diseases

    Significantly Elevated Serum NfL Levels in Symptomatic ALSP vs Other Neurodegenerative Diseases Healthy (25) Prodromal (4) Symptomatic (7) CSF NfL (pg/ml) Left figure: Interim data from Vigil’s Natural History Study in ALSP, ILLUMINATE; right figure: Delaby et al Scientific Reports 2020; control: co

  53. Slide 53: Key Takeaways

    Vigil’s ILLUMINATE & IGNITE Interim Data – Key Takeaways ILLUMINATE & IGNITE represent 1st ever trials of their kind in ALSP Increasing overall understanding of disease pathophysiology, and biomarkers for disease progression and treatment response Positive interim data on VGL101’s potential as treat

  54. Slide 54: Closing Remarks

    Closing Remarks Ivana Magovčević-Liebisch, PhD, JD Chief Executive Officer Vigil Neuroscience, Inc. © Vigil Neuroscience, Inc. 2023. All rights reserved.

  55. Slide 55: Iluzanebart (VGL101): The Only Targeted Therapeutic in Development for ALSP

    Iluzanebart (VGL101): The Only Targeted Therapeutic in Development for ALSP © Vigil Neuroscience, Inc. 2023. All rights reserved. First company to show clinical data on TREM2 agonism as a potential therapeutic approach in patients with a neurodegenerative disease VGL101 demonstrated favorable safety

  56. Slide 56: Q&A

    Q&A VIGILANT FOR YOU is a registered trademark of Vigil Neuroscience, Inc. VIGIL NEUROSCIENCE and the Vigil Neuro logo is a trademark of Vigil Neuroscience, Inc.

Vigil Neuroscience — Technical Presentation (November 2023) on 6ix